ACUTE MYELOID LEUKEMIA (AML)
This test assesses genetic mutations in AML patients with normal cytogenetics. It focuses on FLT3, NPM1, and CEBPA mutations that can impact disease prognosis. The results guide therapeutic choices for patients without major chromosomal abnormalities.
ACUTE MYELOID LEUKEMIA (AML) Package in Vadodara Overview
No special preparations needed
- Specimen Source
- Preliminary Report
- Flt3 Itd Mutation
- Flt3 Itd Signal Ratio (mutant: Wildtype)
- Flt3 D835 Mutation
- Clinical Details
- Specimen Source
- Preliminary Report
- Npm1 Mutation
- Clinical Details
- Specimen Source
- Preliminary Report
- Cebpa Mutation
This test identifies molecular abnormalities in Acute Myeloid Leukemia (AML) patients without major chromosomal changes.
Patients diagnosed with AML who require genetic profiling for targeted treatment should consider this test.
A bone marrow or blood sample undergoes genetic analysis.
Certain mutations can influence prognosis and treatment response.
Yes, through chemotherapy, targeted therapy, or stem cell transplants.
Test code
9303
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Bone Marrow | Others | 5 ML |
| Edta Whole Blood | Lavender Vacutainer | 8 ML |
Specimen stability information
Bone Marrow, Edta Whole Blood
Collection instructions
Clinical History
Specimen rejection criteria
Test run frequency
'
Turn around time
7 Working Days
Performing locations
Department
- Advanced Molecular Diagnostics R&d
CPT and Loinc codes
Package price
₹13500
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestACUTE MYELOID LEUKEMIA (AML)
₹13500